

# HOW TESTING FOR gBRCA HAS CHANGED THROUGH THE YEARS

## Then

### BC RISK MANAGEMENT

Historically, gBRCA testing has been used for risk management and prevention.<sup>1</sup>

According to the NCCN Guidelines<sup>®</sup> for *Genetic/Familial High-Risk Assessment: Breast & Ovarian*, BRCA1/2 testing is recommended for your patients with a BC diagnosis who meet certain criteria including but not limited to<sup>13</sup>:

- BC diagnosed at ≤45 years
- TNBC diagnosed at ≤60 years
- A known mutation in a cancer susceptibility gene within the family

## Now

### MAY INFORM TREATMENT DECISIONS

In the last decade, BRCA genetic testing has gained clinical importance as a diagnostic and biomarker tool to guide breast cancer treatment decisions.<sup>1</sup>

According to *NCCN Guidelines for Breast Cancer*, BRCA1/2 testing should be strongly considered for patients with HER2-negative tumors eligible for single-agent therapy. Genetic counseling for patients at high risk for hereditary breast cancer also is recommended.<sup>14</sup>

Understanding whether your MBC patient has a gBRCA mutation at diagnosis may inform their treatment plan.<sup>1</sup>

**References:** **1.** Moreno L, Linossi C, Esteban I, et al. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. *Clin Transl Oncol*. 2016;18(10):981-987. **13.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Genetic/Familial High-Risk Assessment: Breast & Ovarian V.2.2019. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed July 30, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. **14.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 23, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.